Thromboembolism Clinical Trials

Birmingham :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Montgomery : Baptist Health

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Glendale : Arrowhead Hospital/Phoenix Heart, PLLC

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Little Rock : Arkansas Children's Hospital Research Institute

Treatment of Blood Clots in Children With Cancer

La Mesa :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Long Beach :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Modesto : Memorial Medical Center

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Orange : St. Joseph Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Palo Alto : Stanford University Medical Center

Treatment of Blood Clots in Children With Cancer

View More »

San Diego :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Stanford : Stanford University Medical Center

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Stanford :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Stanford : Stanford University Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Wheat Ridge :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Danbury : Danbury Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Hartford : Hartford Hospital

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Norwich : Eastern Connecticut Hematology and Oncology Associates

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Newark : Christiana Care Health Systems

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Washington : Georgetown University Lombardi Cancer Center

Treatment of Blood Clots in Children With Cancer

Bay Pines :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Clearwater :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Jacksonville :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Jacksonville : Nemours Children's Clinic/Jacksonville

Treatment of Blood Clots in Children With Cancer

Melbourne : Holmes Regional Medical Center

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

View More »

Orlando : Orlando Regional Medical Center

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Orlando : Florida Hospital

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Orlando : Florida Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Sarasota :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Tampa : Pepin Heart Hospital / University Community Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Tampa : St. Joseph's Children's Hospital of TampaPediatric Hematology/Oncology Research Department

Treatment of Blood Clots in Children With Cancer

Vero Beach :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Atlanta : Emory University

Treatment of Blood Clots in Children With Cancer

Decatur :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Macon : Medical Center of Central Georgia

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Chicago : University of Illinois at Chicago

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Chicago : Rush University Medical Center

Treatment of Blood Clots in Children With Cancer

Hinsdale : Adventist Midwest Health

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Oak Park :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Springfield : Prairie Heart Institue

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

View More »

Springfield : Southern Illinois University

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Winfield : Central DuPage Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Carmel :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Indianapolis : St. Vincent Hospital

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Indianapolis : CorVasc

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Iowa City : University of Iowa Carver's College of Medicine

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Windsor Heights :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Topeka :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Florence : St. Elizabeth Healthcare of Northern Kentucky

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Lexington : University of Kentucky, Gill Heart Institute

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Louisvile : Kosair Charities Pediatric Clinical Research Unit- University of Louisville

Treatment of Blood Clots in Children With Cancer

New Orleans : East Jefferson General Hospital

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Portland : Maine Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Annapolis :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Boston : Massachusetts General Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Ann Arbor : Ann Arbor Veteran's Administration Health System

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Ann Arbor : University of Michigan Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Detroit :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Detroit : Henry Ford Health System

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Detroit : Detroit Medical Center

Fondaparinux in Critically Ill Patients With Renal Failure

View More »

Southfield : Providence Hospital

AMPLATZER Cardiac Plug Clinical Trial

Duluth :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Rochester : Mayo Clinic

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Picayune :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

St. Louis :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

St. Louis : Washington University School of Medicine

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Butte :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Lincoln : Saint Elizabeth Regional Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Omaha :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Reno :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Morristown : Overlook Medical Center

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Teaneck : Holy Name Hospital

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Teaneck : Holy Name Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Albuquerque : University of New Mexico

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Albuquerque : University of New Mexico

Treatment of Blood Clots in Children With Cancer

Buffalo : Roswell Park Cancer Institute

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

New York : Cornell Weill Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Rochester : University of Rochester Medical Center

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

Rochester : Rochester General Hospital

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

Staten Island :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

View More »

Staten Island : Staten Island University Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Chapel Hill : University of North Carolina at Chapel Hill

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Durham : Duke University School of Medicine

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

Durham :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Durham : Duke University

Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism

Durham : Duke Children's Hospital

Treatment of Blood Clots in Children With Cancer

View More »

Winston Salem : Wake Forest University Baptist Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Winston-Salem : Forsyth Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Cincinatti : Good Samaritan Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Cleveland :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Cleveland : Cleveland Clinic

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Colombus : Univeristy Medical Center

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Columbus : Mt. Carmel East

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

View More »

Columbus : Riverside Methodist Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Toledo : Jobst Vascular Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Portland : Oregon Health & Science University

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Portland : Oregon Health and Science University

Treatment of Blood Clots in Children With Cancer

Bethlehem : St. Luke's Hospital and Health Network

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Camp Hill :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Philadelphia : Albert Einstein Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Philadelphia : Temple University Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Pittsburgh : Allegheny General Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

View More »

Pittsburgh : The Western Pennsylvania Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Pittsburgh : University of Pittsburgh Medical Center Presbyterian Shadyside

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

West Reading : The Reading Hospital and Medical Center

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Providence : Rhode Island Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Charleston : Medical University of South Carolina

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Charleston : Medical Center of South Carolina

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Orangeburg :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Memphis : St. Jude Children's Research Hospital

Treatment of Blood Clots in Children With Cancer

Bellaire :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Corsicana :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Dallas :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

El Paso : Providence Memorial and Sierra Medical Center

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Forth Worth : Cook Children's Medical Center

Treatment of Blood Clots in Children With Cancer

View More »

Houston : 1160.145.00001 Boehringer Ingelheim Investigational Site

Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

San Antonio :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Salt Lake City : University of Utah

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Alexandria : Inova Alexandria Hospital

A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).

Charlottesville : University of Virginia Health System

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Richmond :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Tacoma : MultiCare Health System

A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).

Milwaukee : Medical College of Wisconsin/Froedtert Hospital

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Herston :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Lismore :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Redcliffe :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Graz :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Graz : 1160.86.43001 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Wien :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Wien : 1160.84.4301 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

View More »

Wien : 1160.84.4310 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Wien : 1160.89.43001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Wien : 1160.86.43003 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Brussel : 1160.89.32003 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Bruxelles :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Huy :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Leper :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Leuven :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

View More »

Yvoir :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Valinhos : LAL Clinica Pesquisa e Desenvolvimento Ltda

Efficacy And Safety Of Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass

Valinhos : LAL Clinica Pesquisa e Desenvolvimento Ltda

Efficacy And Safety Of Unfractionated Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass

Valinhos : Lal Clinica Pesquisa E Desenvolvimento Ltda

Efficacy of Sodium Heparin in Prophylaxis of Venous Thromboembolism in Surgical Patients

Gabrovo :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Pleven :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Sofia :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Charlottetown : 1160.86.01003 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Edmonton : 1160.89.00002 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Halifax : QE II Health Sciences Centre

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Hamilton : Hamilton Health Sciences Corporation-General Hospital

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Hamilton : Hamilton Health Sciences Corporation-Henderson Site

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

View More »

Hamilton : Hamilton Health Sciences Corporation-McMaster Site

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Montreal : SMBD Jewish General Hospital

Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism

Montreal : Montreal General Hospital

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Montreal : SMBD Jewish General Hospital

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Montréal : Maisonneuve Rosemont Hospital

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Oshawa : Isis Investigational Site

Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS FXI Rx in Total Knee Arthroplasty

Ottawa : Ottawa Hospital Research Institute (OHRI)

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

Ottawa : Ottawa Health Research Institute

Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism

Ottawa : Ottawa Hospital-General Campus

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Ottawa : 1160.89.00001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Ottawa : University of Ottawa Heart Institute

Strategy of Continued Versus Interrupted Dabigatran at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events

Red Deer : 1160.86.01001 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Saskatoon : Saskatchewan Drug Research Institute

Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism

Toronto : University Health Network - Toronto General Hospital

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Toronto : 1160.89.00005 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Vancouver : Diamond Health Care Centre

Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer

Krapinske Toplice :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Rijeka :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Zagreb :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Brno : 1160.86.42001 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Kyjov :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Liberec :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Litomysl :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Olomouc :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

View More »

Olomouc : 1160.86.42003 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Ostrava :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Prague : 1160.86.42004 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Prague 5 : 1160.86.42002 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Praha 1 :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Praha 10 :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Usti nad Labem :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Zlin :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Frederiksberg :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Haderslev :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Hellerup :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Hillerod :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Hvidovre :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

View More »

Kobenhavn NV :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Silkeborg :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Slagelse :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Tallinn :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Tartu :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Angers : CHU d'Angers

Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)

Angers : 1160.84.3311 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Angoulême : CH d'Angoulême

Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)

Bois Guillaume Cédex : 1160.84.3318 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Bordeaux : 1160.84.3334 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

View More »

Brest :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Brest : HIA Clermont-Tonnerre

Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)

Brest : Medical Intensive Care Unit

Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)

Caen Cedex 5 : 1160.84.3303 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Castelnau Le Lez : Clinique du Parc CASTELNAU LE LEZ

National Evaluation of the Adherence to Recommendations of Venous Thrombo Embolism Treatment in Cancer Patients

Clermont-Ferrand cedex 1 : 1160.84.3314 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Corbeil Essonne : CH de Corbeil Essonne

Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)

Creteil : 1160.84.3320 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Dijon : CHU de Dijon

Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)

Dijon : University Hospital

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

DIJON Cédex : 1160.84.3307 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Grenoble : University Hospital

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Illkirch : 1160.84.3310 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Le Havre : 1160.84.3335 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Les Lilas : 1160.84.3326 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Lille cedex : 1160.84.3304 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Lyon : 1160.84.3312 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Marseille : 1160.84.3305 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Marseille : 1160.89.33002 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

MARSEILLE Cédex 05 : 1160.84.3330 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Metz : 1160.84.3325 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Montauban : CH Montauban

Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)

Montauban : 1160.84.3333 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Morlaix : CH de Morlaix

Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)

Nancy : Laboratoire d'Hémostase Hôpital de Brabois

Thromboprophylaxis and Bariatric Surgery

Nancy : Service de Chirurgie Digestive Hôpital de Brabois

Thromboprophylaxis and Bariatric Surgery

Nancy : Département d'Anesthésiologie Hôpital de Brabois

Thromboprophylaxis and Bariatric Surgery

Nantes : Service de chirurgie générale et digestive,Hôpital Hôtel Dieu

Thromboprophylaxis and Bariatric Surgery

Nantes Cédex 2 : 1160.84.3323 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Paris : Medical Intensive Care Unit

Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)

Paris : 1160.84.3327 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Paris : 1160.84.3302 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Paris : 1160.84.3306 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Paris : 1160.89.33001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Paris cedex 10 : 1160.84.3309 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Pierre Bénite cedex : 1160.84.3313 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Poitiers : CHU de Poitiers

Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)

Poitiers Cédex : 1160.84.3324 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Saint Etienne Cédex 2 : 1160.84.3322 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Saint Herblain Cédex : 1160.84.3321 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Saint Malo : CH de St Malo

Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)

Saint Saulve : 1160.84.3319 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Strasbourg : Centre investigation Clinique Hôpital Civil

Thromboprophylaxis and Bariatric Surgery

Strasbourg : Clinique de l'Orangerie

Thromboprophylaxis and Bariatric Surgery

Strasbourg : Département d'Anesthésiologie Hôpital Civil

Thromboprophylaxis and Bariatric Surgery

Strasbourg : Laboratoire d'hémostase Hôpital de Hautepierre

Thromboprophylaxis and Bariatric Surgery

Strasbourg : Service de Chirurgie Digestive Hopital de Hautepierre

Thromboprophylaxis and Bariatric Surgery

Strasbourg : Service de Chirurgie Générale et Endocrinienne Hôpital Civil

Thromboprophylaxis and Bariatric Surgery

Toulouse Cedex 9 : 1160.84.3317 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Toulouse Cédex 9 : 1160.84.3316 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Tours : CHU de Tours

Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)

Vannes Cédex : 1160.84.3332 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Berlin :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Bochum : 1160.84.04953 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Bonn :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Dresden :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Garmisch-Partenkirchen : 1160.84.04912 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

View More »

Gelnhausen : 1160.84.4922 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Magdeburg :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Münster : 1160.84.04951 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Neuss :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Olsberg : 1160.84.04913 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Witten :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Zwickau : Heinrich-Braun-Klinikum Zwickau gemeinnützige GmbH

Management and Detection of Atrial Tachyarrhythmias in Patients Implanted With BIOTRONIK DX Systems

Balassagyarmat :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Hyderabad : Care Hospital

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

New Delhi : Sir Ganga Ram Hospital

PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.

Afula :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Ashkelon :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Haifa :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Holon :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Jerusalem :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

View More »

Kfar Saba :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Nahariya :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Safed :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Tel Aviv :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Zerifin :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Bollate :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Bologna : University Hospital

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Castelfranco Veneto :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Latina : 1160.84.03908 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Milan : IRCCS H San Raffaele

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

View More »

Milano :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Milano : 1160.84.03902 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Monza : 1160.84.03904 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Monza : 1160.84.03903 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Parma :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Piacenza :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Roma :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Roma : 1160.89.39001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Udine : 1160.84.03909 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Varese :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Vittorio Veneto TV :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Many Locations :

Xarelto Regulatory Post-Marketing Surveillance

Daugavpils :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Liepaja :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Riga :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Riga : 1160.89.37101 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Valmiera :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Kaunas :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Klaipeda :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Siauliai :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Vilnius :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Vilnius : 1160.89.37001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Nijmegen : 1160.89.31003 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Utrecht : 1160.89.31004 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Bergen : 1160.89.47001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Bialystok :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Bydgoszcz :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Czeladz :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Gdansk :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Krakow :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

View More »

Skierniewice :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Tarnobrzeg :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Warszawa :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Kemerovo :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Samara :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

St. Petersburg :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Yaroslavl :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Singapore :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Cape Town :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Johannesburg :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Alicante : University Hospital

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Badalona (Barcelona) : 1160.84.3409 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Barcelona :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Barcelona : 1160.84.3410 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

L'Hospitalet de Llobregat :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

View More »

Linares, Jaén : 1160.84.3413 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Madrid :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Madrid :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Madrid : 1160.84.3408 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Madrid : 1160.84.3403 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Madrid : 1160.89.34001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Madrid : 1160.89.34002 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Majadahonda :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Malaga : 1160.84.3405 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Orihuela :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Pamplona : 1160.84.3404 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Pozuelo de Alarcón - Madrid : 1160.84.3412 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Sabadell :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

San Sebastián de los Reyes :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Sant Boi de Llobregat :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Soria : General Hospital

STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism

Tarragona :

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Valencia : 1160.84.3411 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Valencia : 1160.84.3401 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Zaragoza : 1160.84.3402 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Hässleholm : 1160.86.46002 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Kungälv : 1160.84.4603 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Mölndal : 1160.86.46001 Boehringer Ingelheim Investigational Site

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Motala : 1160.84.4601 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

View More »

Stockholm : Karolinska University Hospital

Compression Treatment Effects on Complications and Healing of Achilles Tendon Rupture

Geneva : Hopitaux Universitaires de Geneve

Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism

Many Locations :

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy

Zürich : 1160.89.41001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Bangkok : 1160.89.66001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Dnipropetrovsk : 1160.89.38001 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Lugansk : 1160.89.38002 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Vinnytsya : 1160.89.38003 Boehringer Ingelheim Investigational Site

Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age

Basildon : 1160.84.04405 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Bedford : 1160.84.04408 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Luton : 1160.84.04403 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Wigan : 1160.84.04401 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Yeovil : 1160.84.04407 Boehringer Ingelheim Investigational Site

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery